NUK - logo
E-viri
Celotno besedilo
Recenzirano
  • Kidney Failure After Occlus...
    Maurer, K.; Verloh, N.; Lürken, L.; Zeman, F.; Stroszczynski, C.; Pfister, K.; Kasprzak, P. M.; Gnewuch, C.; Wildgruber, M.; Wohlgemuth, W. A.; Müller-Wille, R.

    Cardiovascular and interventional radiology, 12/2019, Letnik: 42, Številka: 12
    Journal Article

    Purpose To evaluate the incidence of acute renal failure and chronic kidney disease due to occlusion of accessory renal arteries during endovascular aneurysm repair of infrarenal abdominal aortic aneurysm. Material and Methods We retrospectively reviewed the course of 181 patients (mean age, 71, SD ± 9  years) who underwent EVAR of infrarenal abdominal aortic aneurysm. The renal vessel anatomy was analyzed in all pre- and postoperative CT scans. Diameter and origin of accessory renal arteries were evaluated. Renal function was determined by pre- and postoperative serum creatinine and eGFR levels. Long-term follow-up (>3 months) of patients was available in 121 cases (66.9%). Acute kidney injury and chronic kidney failure were defined according to guidelines of “Kidney Disease: Improving Global Outcomes” (KDIGO). Results In 65 of 181 patients (33.9%), 82 accessory renal arteries were identified preoperatively. In 19 of 181 patients (10.5%), one or more accessory renal arteries were covered and subsequently occluded by the implanted stent-graft device. Neither acute kidney injury (10.3% vs 12.5%; p  = .785) nor chronic kidney disease (10.7% vs 15.38%; p  = .452) was detected significantly more often in patients with covered accessory renal artery. The only significant predictor of acute kidney injury was the preoperative serum creatinine level (1.12 mg/dl vs. 0.98 mg/dl; p  = .03). Significant predictors for chronic kidney disease were preoperative serum creatinine, eGFR, and impaired renal function ( p  < .001). Conclusion Coverage of accessory renal artery due to stent-graft does not lead either to temporary acute kidney injury after endovascular aneurysm repair or to chronic kidney disease. Level of Evidence Level II b.